325 related articles for article (PubMed ID: 23591566)
1. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
Medrano MÁ; Álvarez-Valdés A; Perles J; Lloret-Fillol J; Muñoz-Galván S; Carnero A; Navarro-Ranninger C; Quiroga AG
Chem Commun (Camb); 2013 May; 49(42):4806-8. PubMed ID: 23591566
[TBL] [Abstract][Full Text] [Related]
2. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
Cubo L; Hambley TW; Sanz Miguel PJ; Carnero A; Navarro-Ranninger C; Quiroga AG
Dalton Trans; 2011 Jan; 40(2):344-7. PubMed ID: 20936210
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
4. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
Xu Z; Wang Z; Yiu SM; Zhu G
Dalton Trans; 2015 Dec; 44(46):19918-26. PubMed ID: 26514681
[TBL] [Abstract][Full Text] [Related]
5. Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(II) complexes bearing aliphatic amine ligands.
Cubo L; Casini A; Gabbiani C; Mastrobuoni G; Messori L; Jiménez-Barbero J; Navarro-Ranninger C; Quiroga AG
Chemistry; 2009 Sep; 15(36):9139-46. PubMed ID: 19655350
[TBL] [Abstract][Full Text] [Related]
6. Studies on the photoactivation of two cytotoxic trans,trans,trans-diazidodiaminodihydroxo-Pt(IV) complexes.
Westendorf AF; Bodtke A; Bednarski PJ
Dalton Trans; 2011 May; 40(19):5342-51. PubMed ID: 21461431
[TBL] [Abstract][Full Text] [Related]
7. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
8. Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes.
Cubo L; Quiroga AG; Zhang J; Thomas DS; Carnero A; Navarro-Ranninger C; Berners-Price SJ
Dalton Trans; 2009 May; (18):3457-66. PubMed ID: 19381408
[TBL] [Abstract][Full Text] [Related]
9. New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin.
Ramos-Lima FJ; Quiroga AG; García-Serrelde B; Blanco F; Carnero A; Navarro-Ranninger C
J Med Chem; 2007 May; 50(9):2194-9. PubMed ID: 17407274
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
11. What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt E; Gibson D
J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
[TBL] [Abstract][Full Text] [Related]
12. Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs.
Shi H; Romero-Canelón I; Hreusova M; Novakova O; Venkatesh V; Habtemariam A; Clarkson GJ; Song JI; Brabec V; Sadler PJ
Inorg Chem; 2018 Nov; 57(22):14409-14420. PubMed ID: 30365308
[TBL] [Abstract][Full Text] [Related]
13. Platinum(iv) anticancer prodrugs - hypotheses and facts.
Gibson D
Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
[TBL] [Abstract][Full Text] [Related]
14. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
15. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.
Varbanov HP; Valiahdi SM; Kowol CR; Jakupec MA; Galanski MS; Keppler BK
Dalton Trans; 2012 Dec; 41(47):14404-14415. PubMed ID: 22886297
[TBL] [Abstract][Full Text] [Related]
16. Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy.
Höfer D; Varbanov HP; Legin A; Jakupec MA; Roller A; Galanski MS; Keppler BK
J Inorg Biochem; 2015 Dec; 153():259-271. PubMed ID: 26365319
[TBL] [Abstract][Full Text] [Related]
17. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
18.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
19. Biological activity of a series of cisplatin-based aliphatic bis(carboxylato) Pt(IV) prodrugs: how long the organic chain should be?
Zanellato I; Bonarrigo I; Colangelo D; Gabano E; Ravera M; Alessio M; Osella D
J Inorg Biochem; 2014 Nov; 140():219-27. PubMed ID: 25171667
[TBL] [Abstract][Full Text] [Related]
20. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]